PBS Changes from 1 July 2025

Information relating to the new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on 1 July 2025 is available to download.

USANZ Members may be particularly interested in items related to:

• Unresectable/metastatic urothelial carcinoma (nivolumab)
  Nivolumab (40 mg/4 ml injection, 4 ml vial; 100 mg/10 ml injection, 10 ml vial) (Opdivo®) is now listed on the PBS for the treatment of unresectable or metastatic urothelial carcinoma. Prescriptions for initial and continuing treatments are Authority required (STREAMLINED).
• Trachoma/urethritis/cervicitis (azithromycin)
  Azithromycin (500 mg tablet) (Azithromycin Tablets, USP 500 mg (Precision Dose, USA)®) for the treatment of trachoma; urethritis and cervicitis is now listed on the PBS for the current supply shortage under Section 19A. Azithromycin is listed as a restricted benefit.

Download the PDF: PBS Listings 1 July 2025

This information relates to the administration of these listings by Services Australia. For further information, please download the Frequently Asked Questions. For information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.